HairClone
HairClone is a UK biotech operating the world's first licensed hair follicle banking service and developing personalised dermal papilla cell therapy for androgenic alopecia. It serves patients globally through a B2B2C network of hair restoration clinic partners across the UK, US, Central America, and Australia.
- Company typePrivate
- Founded2015
- HeadquartersManchester, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What HairClone does
HairClone is a UK-based biotechnology company founded in Manchester in 2015, operating the world's first licensed hair follicle banking service and developing a personalised cell therapy for androgenic alopecia (pattern hair loss) in men and women. The company's core commercial product is follicle banking: approximately 100-120 hair follicles are surgically extracted from non-miniaturising regions of the scalp at partner clinics and cryopreserved at -196°C with an established UK tissue bank, preserving cellular activity and genetic profile for future use. Its in-development therapy multiplies dermal papilla cells from banked follicles by over 1000x for injection back into thinning scalp regions to rejuvenate miniaturising follicles, with an additional DP Cell Secretome research programme in the pipeline.
The company runs a B2B2C go-to-market through a tiered Clinical Partner and Banking Associate network of hair restoration surgeons across the UK, US, Central America (Guatemala), and Australia (training underway). Revenue mechanics consist of a one-time follicle banking fee plus an annual storage subscription; the larger per-treatment cell therapy revenue stream remains contingent on clinical validation. Clinical testing of the cell therapy commenced in March 2026 at the Schambach Hair Clinic in Guatemala, supported by a newly built GMP manufacturing facility co-located in a Guatemalan private hospital. The team is small (1-10 employees), anchored by CEO Paul Kemp, Medical Directors Dr Bessam Farjo and Dr Nilofer Farjo (co-founders of Farjo Hair Institute), a Birmingham-based research group at BioHub, and a laboratory technician embedded in Guatemala.
HairClone is privately held, independent, and pre-commercial on its therapy, having received the European Commission Seal of Excellence (2019), an Innovate UK grant (2024), and the GHP Follicle Biotechnology Company of the Year award (2023). Multiple former ISHRS presidents sit on its clinical and scientific advisory network, providing reputational and distribution leverage in the global hair restoration surgery community.
HairClone firmographics
Firmographics- Name
- HairClone
- Legal name
- HairClone Ltd
- Website
- https://hairclone.me
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- HairClone is a UK biotech operating the world's first licensed hair follicle banking service and developing personalised dermal papilla cell therapy for androgenic alopecia. It serves patients globally through a B2B2C network of hair restoration clinic partners across the UK, US, Central America, and Australia.
- Ownership category
- akta.pro rank
HairClone industry classification
Industry- Product category
- Regenerative Hair Restoration Biotechnology
- NAICS
- Hair, Nail, and Skin Care Services (81211)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844)
- akta.pro primary industry
- Hair Treatments & Scalp Care (Keratin/Botox/Deep Conditioning) (HSALAAAF)
Keywords
Where HairClone is headquartered
LocationHeadquarters
- HQ city
- Manchester
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
HairClone business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Follicle Banking Service: One-time banking fee plus annual storage fee for cryopreserving hair follicles. Price dependent on location and surgical technique. Available at partner clinics in UK and US, with expansion to Central America and Australia.
- Cell Therapy Treatment (Future): When clinical testing completes and treatment becomes available, patients will pay for the dermal papilla cell injection therapy. This will be administered at partner clinics following follicle banking.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | One-time follicle banking fee plus annual storage fee |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
HairClone product offering
Product offeringCore offering
HairClone provides a licensed Hair Follicle Banking Service that cryopreserves approximately 100–120 surgically extracted hair follicles at -196°C for patients' future use, and is developing a personalised cell therapy that multiplies a patient's own dermal papilla cells over 1,000-fold for injection into thinning scalp regions to treat androgenic alopecia. The service is delivered through a global network of partner hair transplant clinics.
Product overview
HairClone operates as a biotechnology company offering two core products: (1) the World's First Licensed Hair Follicle Banking Service for cryopreserving hair follicles, and (2) a Personalised Cell Therapy in development that multiplies dermal papilla cells from banked follicles for injection to rejuvenate miniaturising hair follicles. The company also maintains a DP Cell Secretome research programme. The follicle banking service is the commercial foundation (available now), while cell therapy represents the future treatment offering.
Differentiator
Problem solved
Functional benefit
Products and services
- Hair Follicle Banking Service Licensed service that cryopreserves approximately 100–120 surgically extracted hair follicles from non-miniaturising regions of the scalp at -196°C, maintaining metabolic activity and genetic profile for future personalised cell therapy use. Available through partner hair transplant clinics in the UK and US.
- Personalised Cell Therapy Cell therapy in clinical development that multiplies a patient's own dermal papilla cells from cryopreserved follicles over 1,000-fold and injects them into miniaturising areas of the scalp to rejuvenate thinning hairs, treating androgenic alopecia (pattern hair loss) in men and women. Treatment will be administered at partner clinics.
- DP Cell Secretome
Quantifiable outcome
- Over 1000x multiplication of dermal papilla cells from banked follicles
- +2 more outcomes
Companies that use HairClone
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
HairClone technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
HairClone partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- Schambach Hair Clinic (Dr Marie Schambach)coreClinical Partner collaboration in Guatemala hosting HairClone's GMP manufacturing facility. Cells are grown under GMP conditions at the facility and injected back into patients at the clinic. Dr Schambach founded the clinic in 2010 and is former president of SILATC.
- Dr Epameinondas Bonaros (Glasgow, Scotland)coreBanking Partner offering hair follicle banking services at his clinic in Glasgow, Scotland. Award-winning surgeon (2025 'Best Hair Restoration of the Year' Scottish Aesthetic Awards), Scotland's only ISHRS member.
- Dr Carlos K. Wesley clinic (New York City)coreBanking Associate offering follicle banking at his Fifth Avenue clinic. Facility has Joint Commission accreditation. Founder/CEO of Pilofocus (biomedical technology for scarless surgical hair treatments). Yale University School of Medicine graduate.
- BioHub Birmingham / Birmingham Research ParkcoreResearch laboratory facilities based at BioHub Birmingham, a fully serviced biomedical laboratory space run by University of Birmingham housing early-stage life science companies.
- Dr Summik Limbu (Imperial College London)minorPhD student co-sponsored by HairClone with Dr Claire Higgins at Imperial College London. Awarded Jurgen Schweizer Prize for best oral presentation at EHRS 2023 for research on genetic factors in androgenetic alopecia.
- University of Birmingham (B-Experienced Internship Scheme)minorPartnership through B-Experienced Internship Scheme connecting local businesses with current students and recent graduates from the University of Birmingham.
- Cooley Hair Center (Dr Jerry Cooley)coreClinical Partner since early stages, with 25+ years of surgical hair restoration experience. Former ISHRS president. Presented at BAHRS conference on dealing with poor growth results.
- The Knudsen Clinic (Dr Russell Knudsen)coreClinical Partner since early stages, with 38+ years of hair transplant surgery across multiple sites in Australia and New Zealand. Former ISHRS president. Has ARTAS robot and offers revision surgery.
- Farjo Hair Institute (Dr Bessam Farjo and Dr Nilofer Farjo)coreCo-founders and Medical Directors of HairClone. Founded Farjo Hair Institute in 1993 with 30 years of experience. Dr Nilofer Farjo served as ISHRS president (2021-2022).
- California Hair Surgeon (Dr Sara Wasserbauer)coreOriginally joined as Banking Partner in 2020, enhanced to full Clinical Partner in January 2026. Offers hair follicle banking service and will have access to dermal papilla cell therapy once available in USA. Dr Wasserbauer serves on ISHRS Board of Governors.
- Dr Jeffrey Epstein (The Foundation for Hair Restoration)coreOriginally Banking Associate (2019), upgraded to Clinical Partner (2020). Board-certified facial plastic surgeon specialising in hair restoration since 1994. Will offer treatments when FDA approved.
- Dr Claire Higgins (Imperial College London)coreScientific Advisory Board member and leading hair researcher studying dermal papilla and bulge cells. President of EHRS 2023 conference. Later awarded Henkel's 'Martha Schwarzkopf Award for Women in Science'.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
HairClone competitors and assessment
Company assessmentDirect peers
- RepliCel Life Sciences (now Replicel): RepliCel is a Canadian-Japanese biotech that developed RCH-01, an autologous cell therapy for hair loss using hair follicle cells. It is a direct historical peer to HairClone, both pioneering autologous follicle cell-based therapies for androgenic alopecia.
- Stemson Therapeutics: Stemson Therapeutics is a San Diego-based biotech using iPSC technology to generate new hair follicles for hair loss treatment. It is a direct peer to HairClone in the cell-based hair regeneration space, both targeting the same androgenic alopecia market with fundamentally different technical approaches.
- Follica: Follica is a clinical-stage biotech developing a device-plus-compound treatment to grow new hair follicles. It is a direct peer in the hair regeneration space, pursuing an alternative regenerative approach to androgenic alopecia compared to HairClone's cell multiplication strategy.
- Stemson Therapeutics (duplicate removed; see above):
- dNovo: dNovo is a biotechnology company developing bioengineered hair growth treatments using cell reprogramming technology. It is a direct competitor to HairClone in the cell therapy for hair loss category, although HairClone focuses on autologous dermal papilla cells while dNovo uses a different reprogramming approach.
Broad incumbents
- Shiseido: Shiseido acquired RepliCel's technology and has been developing cell-based hair loss treatments. As a global beauty incumbent with R&D scale and distribution, Shiseido is a broad incumbent peer competing in the regenerative hair loss space with greater resources than HairClone.
- Aderans: Aderans is a Japanese hair restoration company with a long-running research program in hair multiplication/cell-based therapies. As one of the largest global hair restoration companies with significant R&D investment, it is a broad incumbent peer to HairClone.
- Cole Instruments (ARTAS robotic hair transplant): Cole Instruments markets the ARTAS robotic hair transplant system, the leading automated FUE technology. While a device-based rather than cell-based approach, ARTAS competes with HairClone's eventual cell therapy offering for surgical hair restoration patients.
Emerging players
- Kerastem: Kerastem is a regenerative medicine company developing cell-based therapies for hair loss using adipose-derived stem cells. It represents an emerging player with overlapping regenerative cell therapy goals for hair loss, though using a different cell source than HairClone's dermal papilla cells.
- Histogen: Histogen is a regenerative medicine company developing HairStim, a cell-conditioned media treatment for hair loss. It overlaps with HairClone's DP Cell Secretome program, as both explore cell-secreted factors as a regenerative approach to hair loss.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
HairClone social profiles
Digital presenceHairClone financial estimates
Financial estimateRevenue estimate
Valuation estimate
HairClone leadership team
Management profileNumber of profiles
Profiles6 records
HairClone funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HairClone M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HairClone
What does HairClone do?
HairClone provides a licensed Hair Follicle Banking Service that cryopreserves approximately 100–120 surgically extracted hair follicles at -196°C for patients' future use, and is developing a personalised cell therapy that multiplies a patient's own dermal papilla cells over 1,000-fold for injection into thinning scalp regions to treat androgenic alopecia. The service is delivered through a global network of partner hair transplant clinics.
Is HairClone a public or private company?
HairClone is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was HairClone founded?
HairClone was founded in 2015. It employs 1 to 10 people.
Where is HairClone based?
HairClone is headquartered in Manchester, United Kingdom, in the Europe region.
How does HairClone make money?
Two revenue lines are on record. Follicle Banking Service is the primary driver. The others are cell Therapy Treatment (Future).
Who are HairClone's main competitors?
Direct peers on record are RepliCel Life Sciences (now Replicel), Stemson Therapeutics, Follica, Stemson Therapeutics (duplicate removed; see above) and dNovo. Broad incumbents are Shiseido, Aderans and Cole Instruments (ARTAS robotic hair transplant). Emerging players are Kerastem and Histogen.
Does HairClone have an API?
No public API is recorded for HairClone.
What industry is HairClone in?
HairClone's product category is Regenerative Hair Restoration Biotechnology. Its primary akta.pro industry code is HSALAAAF, Hair Treatments & Scalp Care (Keratin/Botox/Deep Conditioning). Its NAICS code is 81211 and its SIC code is 2844.